Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.

Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M.

PLoS Pathog. 2011 Jan 6;7(1):e1001258. doi: 10.1371/journal.ppat.1001258.

2.

Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Zhao X, Sehgal M, Hou Z, Cheng J, Shu S, Wu S, Guo F, Le Marchand SJ, Lin H, Chang J, Guo JT.

J Virol. 2018 Feb 26;92(6). pii: e01535-17. doi: 10.1128/JVI.01535-17. Print 2018 Mar 15.

3.

IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms.

Wrensch F, Winkler M, Pöhlmann S.

Viruses. 2014 Sep 26;6(9):3683-98. doi: 10.3390/v6093683.

4.

Duck Interferon-Inducible Transmembrane Protein 3 Mediates Restriction of Influenza Viruses.

Blyth GA, Chan WF, Webster RG, Magor KE.

J Virol. 2015 Oct 14;90(1):103-16. doi: 10.1128/JVI.01593-15. Print 2016 Jan 1.

5.

IFITMs restrict the replication of multiple pathogenic viruses.

Perreira JM, Chin CR, Feeley EM, Brass AL.

J Mol Biol. 2013 Dec 13;425(24):4937-55. doi: 10.1016/j.jmb.2013.09.024. Epub 2013 Sep 25. Review.

6.

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step.

Mingo RM, Simmons JA, Shoemaker CJ, Nelson EA, Schornberg KL, D'Souza RS, Casanova JE, White JM.

J Virol. 2015 Mar;89(5):2931-43. doi: 10.1128/JVI.03398-14. Epub 2014 Dec 31.

7.

pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs.

Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, Klenk HD, Weber F, Herold S, Pöhlmann S, Matrosovich M.

J Virol. 2017 May 12;91(11). pii: e00246-17. doi: 10.1128/JVI.00246-17. Print 2017 Jun 1.

8.

IFITM proteins restrict viral membrane hemifusion.

Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu SL.

PLoS Pathog. 2013 Jan;9(1):e1003124. doi: 10.1371/journal.ppat.1003124. Epub 2013 Jan 24.

9.

Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.

O'Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, Varhegyi E, Olinger G, Rong L.

J Virol. 2015 May;89(10):5441-9. doi: 10.1128/JVI.03689-14. Epub 2015 Mar 4.

10.

Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses.

Wrensch F, Karsten CB, Gnirß K, Hoffmann M, Lu K, Takada A, Winkler M, Simmons G, Pöhlmann S.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S210-8. doi: 10.1093/infdis/jiv255. Epub 2015 Jun 1.

11.

Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses.

Hoffmann M, Müller MA, Drexler JF, Glende J, Erdt M, Gützkow T, Losemann C, Binger T, Deng H, Schwegmann-Weßels C, Esser KH, Drosten C, Herrler G.

PLoS One. 2013 Aug 30;8(8):e72942. doi: 10.1371/journal.pone.0072942. eCollection 2013.

12.

Protease inhibitors targeting coronavirus and filovirus entry.

Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G.

Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011. Epub 2015 Feb 7.

13.

Alphavirus Restriction by IFITM Proteins.

Weston S, Czieso S, White IJ, Smith SE, Wash RS, Diaz-Soria C, Kellam P, Marsh M.

Traffic. 2016 Sep;17(9):997-1013. doi: 10.1111/tra.12416. Epub 2016 Jun 24.

14.

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.

Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS, Harrison SC, Dormitzer PR, Farzan M, Rottier PJ, Choe H.

J Biol Chem. 2006 Feb 10;281(6):3198-203. Epub 2005 Dec 8.

15.

Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation.

Qian Z, Dominguez SR, Holmes KV.

PLoS One. 2013 Oct 3;8(10):e76469. doi: 10.1371/journal.pone.0076469. eCollection 2013.

16.

Infection of Mouse Macrophages by Seasonal Influenza Viruses Can Be Restricted at the Level of Virus Entry and at a Late Stage in the Virus Life Cycle.

Londrigan SL, Short KR, Ma J, Gillespie L, Rockman SP, Brooks AG, Reading PC.

J Virol. 2015 Dec;89(24):12319-29. doi: 10.1128/JVI.01455-15. Epub 2015 Sep 30.

17.

IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.

Bailey CC, Zhong G, Huang IC, Farzan M.

Annu Rev Virol. 2014 Nov 1;1:261-283.

18.

Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction.

Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, Aker AM, John SP, Sarlah D, Carreira EM, Elledge SJ, Kellam P, Brass AL.

Cell Rep. 2013 Nov 27;5(4):895-908. doi: 10.1016/j.celrep.2013.10.033. Epub 2013 Nov 21.

19.

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.

Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JS.

J Virol. 2011 Oct;85(20):10582-97. doi: 10.1128/JVI.00671-11. Epub 2011 Jul 20.

20.

Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.

Fukushi S, Watanabe R, Taguchi F.

Methods Mol Biol. 2008;454:331-8. doi: 10.1007/978-1-59745-181-9_23.

PMID:
19057867

Supplemental Content

Support Center